Bright Minds Biosciences Inc.

NasdaqCM:DRUG Stock Report

Market Cap: US$704.5m

Bright Minds Biosciences Management

Management criteria checks 4/4

Bright Minds Biosciences' CEO is Ian McDonald, appointed in May 2019, has a tenure of 7.17 years. directly owns 10.26% of the company’s shares, worth $72.27M. The average tenure of the management team and the board of directors is 4 years and 4.2 years respectively.

Key information

Ian McDonald

Chief executive officer

CA$120.0k

Total compensation

CEO salary percentagen/a
CEO tenure7.2yrs
CEO ownership10.3%
Management average tenure4yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

Seeking Alpha • Jan 07

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Summary Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resistant epilepsies. DRUG's BMB-101 achieved -73.1% and -63.3% median seizure reductions in Absence Epilepsy and DEE cohorts, respectively. Multiple 2026 catalysts include additional phase 2 data, phase 3 trial initiation, and a phase 2 PWS study for BMB-101. Recent $100M financing and ATM program extend the runway, but further capital raises may be needed as clinical programs advance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Summary We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2 2025. The company has a decent balance sheet, with roughly $40.3 million in cash. It may need to raise capital by mid-2026 or earlier as R&D expenses increase. A strategic partnership or acquisition could enhance value if the company's pipeline proves successful in clinic. Read the full article on Seeking Alpha
Seeking Alpha • Aug 18

Bright Minds says no material events fueled rally

After over 100% surge in its share price, Canadian biotech Bright Minds Biosciences (NASDAQ:DRUG) (OTCQB:BMBIF) announced Thursday that the company is unaware of any material events or undisclosed corporate actions that caused today’s rally. The company announced this in response to a request by the Investment Industry Regulatory Organization of Canada, which has sought its comments on its recent trading activity. DRUG, a pre-clinical biosciences company, added ~121% during regular trading on above-average volumes. About 119.5 company shares changed hands, compared to the 65-day average volume of ~58.3K. “The Company is not aware of any material, undisclosed corporate developments and has no material change in its business or affairs that has not been publicly disclosed that would account for the recent increase in volume or price,” Bright Minds (DRUG) said. DRUG shares have lost ~3.2% in post-market trading. Read Seeking Alpha’s “On the Move” section to monitor shares with the biggest moves.

CEO

Ian McDonald (38 yo)

7.2yrs
Tenure
CA$120,000
Compensation

Mr. Ian McDonald was Independent Director of Abpro Holdings, Inc. from November 13, 2024 until January 16, 2026. Mr. McDonald is Co-Founder of Bright Minds Biosciences Inc. and serves as its Chief Executiv...

Leadership Team

NamePositionTenureCompensationOwnership
Ian McDonald
Co-Founder7.2yrsCA$120.00k10.26%
$ 72.3m
Ryan E. S. Cheung
CFO & Corporate Secretary6.2yrsCA$206.57kno data
Jan Pedersen
Chief Science Officer & Director3.8yrsCA$828.73k0.59%
$ 4.1m
Alex Vasilkevich
COO & Senior Scientific Officer2.5yrsno data0.63%
$ 4.4m
Emer Leahy
Consultant4.2yrsno datano data
Stephen Collins
Chief Medical Officer1.5yrsno datano data
4.0yrs
Average Tenure
53.5yo
Average Age

Experienced Management: DRUG's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ian McDonald
Co-Founder7.2yrsCA$120.00k10.26%
$ 72.3m
Jan Pedersen
Chief Science Officer & Director4.3yrsCA$828.73k0.59%
$ 4.1m
Robert Malenka
Member of Scientific Advisory Board4.2yrsno datano data
Herbert Meltzer
Member of Scientific Advisory Board4.2yrsno datano data
David Weiner
Independent Non-Executive Director3.4yrsCA$106.84kno data
Jeremy Fryzuk
Independent Director5.8yrsCA$93.75k0.39%
$ 2.7m
Nils Bottler
Independent Director5.8yrsCA$93.75k0.076%
$ 538.5k
Peter Hendricks
Member of Scientific Advisory Board4.2yrsno datano data
Michael Bogenschutz
Member of Scientific Advisory Board4.2yrsno datano data
Joseph Sullivan
Member of Scientific Advisory Board1.3yrsno datano data
Jo Sourbron
Member of Scientific Advisory Board1.3yrsno datano data
Terence O'Brien
Member of Scientific Advisory Board1.3yrsno datano data
4.2yrs
Average Tenure
51yo
Average Age

Experienced Board: DRUG's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/01 22:24
End of Day Share Price 2026/07/01 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bright Minds Biosciences Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBaird
Charles MooreBaird
Joel BeattyBaird